Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Current Liabilities (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Total Current Liabilities readings, the most recent being $5.6 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 88.21% to $5.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.6 million, a 88.21% decrease, with the full-year FY2025 number at $14.9 million, down 88.91% from a year prior.
  • Total Current Liabilities hit $5.6 million in Q1 2026 for Atara Biotherapeutics, down from $14.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $180.7 million in Q1 2024 to a low of $5.6 million in Q1 2026.
  • Median Total Current Liabilities over the past 5 years was $74.6 million (2023), compared with a mean of $82.5 million.
  • Biggest five-year swings in Total Current Liabilities: surged 166.21% in 2024 and later plummeted 90.18% in 2025.
  • Atara Biotherapeutics' Total Current Liabilities stood at $78.9 million in 2022, then soared by 80.22% to $142.2 million in 2023, then fell by 5.38% to $134.6 million in 2024, then tumbled by 88.91% to $14.9 million in 2025, then crashed by 62.17% to $5.6 million in 2026.
  • The last three reported values for Total Current Liabilities were $5.6 million (Q1 2026), $14.9 million (Q4 2025), and $18.1 million (Q3 2025) per Business Quant data.